Skip to main content
Retour
BHC logo

Bausch Health Companies Inc.

Qualité des données : 100%
BHC
NYSE Healthcare Drug Manufacturers - Specialty & Generic
5,10 €
▲ 0,09 € (1,80%)
Cap. Boursière : 1,89B
Fourchette du Jour
5,01 € 5,19 €
Fourchette 52 Semaines
4,25 € 8,69 €
Volume
1 706 850
Moyenne 50J / 200J
5,98 € / 6,45 €
Clôture Précédente
5,01 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 12,2 0,4
P/B 2,9
ROE % 3,7
Net Margin % 1,5 3,9
Rev Growth 5Y % 5,2 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
8,00 € +56.9%
P/E Prévisionnel
1,2
BPA Prévisionnel
4,36 €
Croissance BPA (est.)
+0,0%
CA Est.
11 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 3,59 €
3,57 € – 3,62 €
9,7 B 1
FY2029 3,33 €
3,31 € – 3,35 €
9,7 B 1
FY2028 3,08 €
3,07 € – 3,10 €
9,8 B 2

Points Clés

Revenue grew 5,15% annually over 5 years — modest growth
Generating 1,00B in free cash flow
P/E of 12,17 — trading at a low valuation
Cash machine — converts 645,94% of earnings into free cash flow
Capital efficient — spends only 3,85% of revenue on capex
Interest coverage of 1,37× — tight debt servicing

Croissance

Revenue Growth (5Y)
5,15%
Revenue (1Y)7,11%
Earnings (1Y)N/A
FCF Growth (3Y)14,88%

Qualité

Return on Equity
N/A
ROIC7,51%
Net Margin1,51%
Op. Margin20,07%

Sécurité

Debt / Equity
N/A
Current Ratio1,47
Interest Coverage1,37

Valorisation

P/E Ratio
12,17
P/B RatioN/A
EV/EBITDA10,52
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7,11% Revenue Growth (3Y) 8,50%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5,15% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10,31B Net Income (TTM) 155,28M
ROE N/A ROA 0,59%
Gross Margin 68,33% Operating Margin 20,07%
Net Margin 1,51% Free Cash Flow (TTM) 1,00B
ROIC 7,51% FCF Growth (3Y) 14,88%
Safety
Debt / Equity N/A Current Ratio 1,47
Interest Coverage 1,37 Dividend Yield 0,00%
Valuation
P/E Ratio 12,17 P/B Ratio N/A
P/S Ratio 0,18 PEG Ratio -0,04
EV/EBITDA 10,52 Dividend Yield 0,00%
Market Cap 1,89B Enterprise Value 21,77B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 10,31B 9,63B 8,76B 8,12B 8,43B
Net Income 155,28M -46,00M -592,00M -225,00M -948,00M
EPS (Diluted) 0,41 -0,13 -1,62 -0,62 -2,61
Gross Profit 7,04B 6,84B 6,20B 5,76B 6,04B
Operating Income 2,07B 1,55B 963,00M 454,00M 450,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 26,32B 26,52B 27,35B 25,69B 29,20B
Total Liabilities 25,94B 26,85B 27,43B 25,43B 29,24B
Shareholders' Equity -552,99M -1,28B -1,02B -692,00M -106,00M
Total Debt 21,21B 21,83B 22,39B 20,77B 22,65B
Cash & Equivalents 1,32B 1,18B 947,00M 564,00M 582,00M
Current Assets 6,15B 5,77B 5,60B 4,25B 5,61B
Current Liabilities 4,17B 6,75B 4,30B 3,94B 5,20B

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#506 of 616
14

Activité Récente

Entré Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026